Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Decreases By 36.1%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 167,500 shares, a drop of 36.1% from the January 31st total of 262,100 shares. Approximately 6.1% of the company’s stock are short sold. Based on an average daily volume of 437,800 shares, the days-to-cover ratio is currently 0.4 days.

Theriva Biologics Price Performance

Theriva Biologics stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.30. 33,000 shares of the company’s stock were exchanged, compared to its average volume of 179,963. The business has a fifty day simple moving average of $1.46. The company has a market capitalization of $3.61 million, a price-to-earnings ratio of -0.04 and a beta of 1.22. Theriva Biologics has a one year low of $1.14 and a one year high of $17.11.

Analyst Upgrades and Downgrades

Separately, Maxim Group dropped their price target on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is owned by institutional investors and hedge funds.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.